Every 8-K that Eloxx Pharmaceut (ELOX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ELOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELOX filings page.
Eloxx Pharmaceuticals reported second quarter 2026 results and a business update, highlighting a significantly strengthened balance sheet following a public offering with gross proceeds of $66.0 million and an uplisting to the Nasdaq Capital Market. As of June 30, 2026, cash and cash equivalents were $62.0 million, including approximately $58.3 million in net proceeds from the June 2026 offering, and the company stated this cash is expected to fund operations into mid‑2028. Total stockholders’ equity improved to $46.4 million from a deficit of $(11.9) million at year‑end 2025.
For the three months ended June 30, 2026, net loss was $4.5 million, or $(0.66) per share, compared with $1.9 million, or $(5.45) per share a year earlier. Research and development expense rose to $2.8 million from $0.9 million, and general and administrative expense increased to $1.6 million from $0.7 million, mainly from higher clinical trial, personnel, and professional fees. For the first half of 2026, net loss was $8.3 million versus $3.6 million in 2025. In May 2026, the company completed a one‑for‑eleven reverse stock split and reduced authorized common shares from 500,000,000 to 100,000,000, and continues to advance its lead candidate exaluren in rare kidney disease indications.
Eloxx Pharmaceuticals disclosed several corporate actions, including a reverse stock split, authorized share reduction, a warrant exchange, and two new independent directors.
The company completed a 1-for-11 reverse stock split of its common stock and reduced authorized common shares from 500,000,000 to 100,000,000, effective at 5:00 p.m. Eastern Time on May 29, 2026. Common stock is expected to begin trading on a split-adjusted basis on June 1, 2026, and will continue on the OTC Pink Market under the symbol ELOX. Proportionate adjustments were made to stock options, restricted stock units, warrants, and plan reserves, with fractional shares rounded down and cashed out based on fair market value at the effective time.
The filing notes that investors holding pre-funded warrants initially issued for 54,076,677 shares exercised warrants for 2,500,000 shares on April 27, 2026, then on May 27, 2026 exchanged those 2,500,000 common shares back into pre-funded warrants for the same number of shares at a $0.01 exercise price in exempt, unregistered transactions.
The board appointed Stephen W. Webster and Nina Kjellson as independent directors to fill vacancies and reduced the board size from six to five. Mr. Webster joins the Audit and Nominating & Corporate Governance Committees and is designated an SEC “financial expert,” while Ms. Kjellson joins the Compensation and Nominating & Corporate Governance Committees. Each entered the standard indemnity agreement and is eligible for non-employee director compensation, including an option to purchase up to 13,587 shares of common stock effective on the date the company’s registration statement becomes effective.
Stockholders holding 57.1% of outstanding voting shares approved, via written consent as of April 28, 2026, both the reverse split within a 1-for-2 to 1-for-20 range and the authorized share reduction, after which the board chose the 1-for-11 ratio and implemented the changes through a Certificate of Amendment filed in Delaware.
Eloxx Pharmaceuticals, Inc. reports that as of the April 28, 2026 record date, there were 7,573,935 shares of common stock outstanding and entitled to vote. On that date, stockholders holding 4,324,964 shares, or 57.1% of the eligible shares, approved certain corporate actions by written consent.
The company has filed a preliminary information statement on Schedule 14C and plans to send a definitive information statement to shareholders. The approved actions will become effective only after the definitive statement is mailed, at least 20 calendar days have passed, and any other required corporate or regulatory conditions are satisfied.